Sunshine Gross Profit from 2010 to 2025

SBFMW Stock

USD 0.22 0.03 12.00%

Sunshine Biopharma Gross Profit yearly trend continues to be fairly stable with very little volatility. Gross Profit is likely to outpace its year average in 2025. Gross Profit is the profit Sunshine Biopharma Warrant makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. View All Fundamentals

Gross Profit

First Reported

2015-06-30

Previous Quarter

2.3 M

Current Value

2.8 M

Quarterly Volatility

1 M

Yuan Drop

Covid

Check Sunshine Biopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Sunshine Biopharma's main balance sheet or income statement drivers, such as Interest Expense of 148.9 K, Other Operating Expenses of 34.9 M or Total Operating Expenses of 15.8 M, as well as many indicators such as Price To Sales Ratio of 0.3, Dividend Yield of 0.0 or PTB Ratio of 0.34. Sunshine financial statements analysis is a perfect complement when working with Sunshine Biopharma Valuation or Volatility modules.

Check out the analysis of Sunshine Biopharma Correlation against competitors.

For more information on how to buy Sunshine Stock please use our How to Invest in Sunshine Biopharma guide.

Latest Sunshine Biopharma's Gross Profit Growth Pattern

Below is the plot of the Gross Profit of Sunshine Biopharma Warrant over the last few years. Gross profit is a required income statement account that reflects total revenue of Sunshine Biopharma Warrant minus its cost of goods sold. It is profit before Sunshine Biopharma operating expenses, interest payments and taxes. Gross profit is also known as gross margin. It is the profit a company makes after deducting the costs associated with making and selling its products, or the costs associated with providing its services. Sunshine Biopharma's Gross Profit historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Sunshine Biopharma's overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 10.14 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Gross Profit

Timeline

Sunshine Gross Profit Regression Statistics

	Arithmetic Mean	1,877,511
	Geometric Mean	45,206
	Coefficient Of Variation	199.01
	Mean Deviation	2,795,779
	Median	56,119
	Standard Deviation	3,736,380
	Sample Variance	14T
	Range	10.1M
	R-Value	0.72
	Mean Square Error	7.2T
	R-Squared	0.52
	Significance	0
	Slope	563,934
	Total Sum of Squares	209.4T

Sunshine Gross Profit History

	2025	10.1 M
	2024	9.6 M
	2023	8.3 M
	2022	1.7 M
	2021	110.6 K
	2020	45.6 K
	2019	10.1 K

Other Fundumenentals of Sunshine Biopharma

Gross Profit Margin

Sunshine Biopharma Gross Profit component correlations

	Total Assets	Total Stockholder Equity	Net Debt	Retained Earnings	Accounts Payable	Total Liab	Total Current Assets	Common Stock	Short Term Debt	Net Receivables	Intangible Assets	Net Tangible Assets	Property Plant Equipment	Current Deferred Revenue	Long Term Debt	Good Will	Net Invested Capital	Short Long Term Debt	Capital Stock	Net Working Capital	Short Term Investments
Total Assets		1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.78	-0.78	0.61	0.77	-0.68	1.0	0.9	-0.58	1.0	-0.68
Total Stockholder Equity	1.0		-0.98	-0.92	1.0	0.97	1.0	-0.31	0.17	0.99	0.78	0.78	-0.75	0.58	0.75	-0.68	1.0	0.88	-0.6	1.0	-0.68
Net Debt	-0.98	-0.98		0.93	-0.98	-0.96	-0.98	0.32	-0.28	-0.95	-0.73	-0.77	0.75	-0.6	-0.77	0.53	-0.99	-0.86	0.6	-0.98	0.53
Retained Earnings	-0.94	-0.92	0.93		-0.93	-0.97	-0.94	0.24	-0.36	-0.91	-0.81	-0.81	0.91	-0.78	-0.9	0.52	-0.93	-0.93	0.49	-0.94	0.52
Accounts Payable	1.0	1.0	-0.98	-0.93		0.98	1.0	-0.31	0.2	0.99	0.78	0.77	-0.77	0.6	0.75	-0.67	1.0	0.88	-0.58	1.0	-0.67
Total Liab	0.98	0.97	-0.96	-0.97	0.98		0.98	-0.28	0.35	0.95	0.75	0.78	-0.85	0.7	0.82	-0.63	0.98	0.91	-0.49	0.98	-0.63
Total Current Assets	1.0	1.0	-0.98	-0.94	1.0	0.98		-0.31	0.22	0.98	0.77	0.78	-0.78	0.62	0.77	-0.67	1.0	0.9	-0.57	1.0	-0.67
Common Stock	-0.31	-0.31	0.32	0.24	-0.31	-0.28	-0.31		-0.06	-0.3	-0.12	-0.38	0.36	-0.31	-0.36	0.18	-0.3	-0.36	0.31	-0.31	0.18
Short Term Debt	0.21	0.17	-0.28	-0.36	0.2	0.35	0.22	-0.06		0.06	-0.14	0.3	-0.41	0.41	0.43	0.21	0.25	0.31	-0.08	0.21	0.21
Net Receivables	0.99	0.99	-0.95	-0.91	0.99	0.95	0.98	-0.3	0.06		0.83	0.76	-0.75	0.57	0.73	-0.73	0.98	0.88	-0.57	0.99	-0.73
Intangible Assets	0.78	0.78	-0.73	-0.81	0.78	0.75	0.77	-0.12	-0.14	0.83		0.63	-0.69	0.64	0.75	-0.5	0.75	0.73	-0.41	0.78	-0.5
Net Tangible Assets	0.78	0.78	-0.77	-0.81	0.77	0.78	0.78	-0.38	0.3	0.76	0.63		-0.7	0.46	0.73	-0.48	0.78	0.87	-0.72	0.79	-0.48
Property Plant Equipment	-0.78	-0.75	0.75	0.91	-0.77	-0.85	-0.78	0.36	-0.41	-0.75	-0.69	-0.7		-0.92	-0.94	0.48	-0.77	-0.9	0.26	-0.79	0.48
Current Deferred Revenue	0.61	0.58	-0.6	-0.78	0.6	0.7	0.62	-0.31	0.41	0.57	0.64	0.46	-0.92		0.92	-0.25	0.6	0.73	-0.13	0.63	-0.25
Long Term Debt	0.77	0.75	-0.77	-0.9	0.75	0.82	0.77	-0.36	0.43	0.73	0.75	0.73	-0.94	0.92		-0.33	0.76	0.9	-0.39	0.79	-0.33
Good Will	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33		-0.65	-0.62	0.36	-0.68	1.0
Net Invested Capital	1.0	1.0	-0.99	-0.93	1.0	0.98	1.0	-0.3	0.25	0.98	0.75	0.78	-0.77	0.6	0.76	-0.65		0.89	-0.58	1.0	-0.65
Short Long Term Debt	0.9	0.88	-0.86	-0.93	0.88	0.91	0.9	-0.36	0.31	0.88	0.73	0.87	-0.9	0.73	0.9	-0.62	0.89		-0.54	0.91	-0.62
Capital Stock	-0.58	-0.6	0.6	0.49	-0.58	-0.49	-0.57	0.31	-0.08	-0.57	-0.41	-0.72	0.26	-0.13	-0.39	0.36	-0.58	-0.54		-0.58	0.36
Net Working Capital	1.0	1.0	-0.98	-0.94	1.0	0.98	1.0	-0.31	0.21	0.99	0.78	0.79	-0.79	0.63	0.79	-0.68	1.0	0.91	-0.58		-0.68
Short Term Investments	-0.68	-0.68	0.53	0.52	-0.67	-0.63	-0.67	0.18	0.21	-0.73	-0.5	-0.48	0.48	-0.25	-0.33	1.0	-0.65	-0.62	0.36	-0.68

Click cells to compare fundamentals

About Sunshine Biopharma Financial Statements

Sunshine Biopharma investors use historical fundamental indicators, such as Sunshine Biopharma's Gross Profit, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Sunshine Biopharma. Please read more on our technical analysis and fundamental analysis pages.

	Last Reported	Projected for Next Year
Gross Profit	9.6 M	10.1 M
Gross Profit Margin	0.31	0.33

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

ZLAB	Zai Lab
ASLE	AerSale Corp
ATS	AT S Austria

Additional Tools for Sunshine Stock Analysis

When running Sunshine Biopharma's price analysis, check to measure Sunshine Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sunshine Biopharma is operating at the current time. Most of Sunshine Biopharma's value examination focuses on studying past and present price action to predict the probability of Sunshine Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sunshine Biopharma's price. Additionally, you may evaluate how the addition of Sunshine Biopharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC